Breaking News, Collaborations & Alliances

Xyphos Biosciences & Kelonia Partner to Develop Novel Immuno-Oncology Therapeutics

Will combine Kelonia's iGPS with Xyphos' ACCEL technology to develop in vivo CAR-T Cell therapies.

Author Image

By: Charlie Sternberg

Associate Editor

Xyphos Biosciences Inc., a wholly owned subsidiary of Astellas Pharma Inc., and Kelonia Therapeutics have entered into a research collaboration and license agreement to develop novel Immuno-Oncology therapeutics.   Kelonia is a biotech company pioneering new genetic medicines using its in vivo gene placement system (iGPS), which uses next generation lentiviral particles to efficiently deliver genetic cargo precisely to the desired target cells inside the patient’s body.   Xyphos holds ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters